Cancer Research UK-funded scientists working on an experimental treatment, initially thought to be helpful for only a minority of patients, have found evidence that it might be able to benefit many more people than first thought.
Although their name suggests an indigestion remedy rather than a chemotherapy, PARP inhibitors are part of a new generation of cancer drugs – and Cancer Research UK has been working on bringing them to the clinic for over a decade.
These drugs are highly targeted to people whose cancers are due to specific genetic faults. Early trial results suggest they can be very effective. But could they work on cancers with other genetic errors?
Read the rest of this entry »
Posted by Kat Arney 
Welcome to the
